See2cure detects the invisible to improve surgery and reduce recurrence of abdominal cancers using a targeted fluorescent guidance technology.
This project addresses a major clinical challenge: the treatment of microscopic abdominal metastases, a frequent consequence of colorectal, gastric, ovarian and pancreatic cancers, which affect more than one million people worldwide every year. The innovative see2cure protein platform has been designed as a fluorescent targeting tracer. It specifically detects these metastases by recognising its molecular target during fluorescence-guided surgery, whether open (laparotomy) or minimally invasive (laparoscopy). The aim of this technology is to improve surgical results and reduce recurrence, which currently affects 75% of patients after first line treatment. It enables early and targeted detection of lesions that are invisible to the naked eye.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 1, Avenue Irène Joliot-Curie, Toulouse,occitanie 31100,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.see2cure.com
- HQ
- Toulouse, Occitanie
See2cure Questions
See2Cure's website is http://www.see2cure.com
See2Cure's LinkedIn profile is https://fr.linkedin.com/company/see2cure
See2Cure has
4 employees.
View email and phone details for 4
employees at See2Cure.
See2Cure's industry is
Biotechnology Research
See2Cure's top competitors are
React Therapeutics,
Lami®,
Proskope,
Iopole,
Serendip Innovations,
Orinova,
Yomi Pharma,
Minos Biosciences,
Embrya Sas,
Starkage Therapeutics.
See2Cure's categories are Biotechnology Research
See2Cure's founding year is 2024
